Efficacy and Safety of Different Doses of Systemic Corticosteroids in COPD Exacerbation

医学 安慰剂 剂量 强的松 恶化 慢性阻塞性肺病 入射(几何) 内科学 有效剂量(辐射) 胃肠病学 随机对照试验 核医学 物理 替代医学 病理 光学
作者
Xiaofeng Pu,Liang Liu,Bimin Feng,Maolin Wang,Limei Dong,Zh. Zhang,Qingze Fan,Ying Li,Guojun Wang
出处
期刊:Respiratory Care [American Association for Respiratory Care]
卷期号:66 (2): 316-326 被引量:5
标识
DOI:10.4187/respcare.07925
摘要

BACKGROUND:

Although systemic corticosteroids (SCS) have long been used to treat patients with COPD exacerbation, the recommended dose remains controversial. We aimed to perform a meta-analysis and an indirect treatment comparison to investigate the efficacy and safety of different doses of SCS in subjects with COPD exacerbation.

METHODS:

Studies were identified by searching different databases for randomized controlled trials that investigated the efficacy and safety of SCS with placebo in subjects with exacerbation of COPD. The different doses of SCS were assigned to low-dose (ie, initial dose ≤ 40 mg prednisone equivalent/d [PE/d]), medium-dose (initial dose = 40–100 mg PE/d, and high-dose (initial dose > 100 mg PE/d) groups. The indirect treatment comparison was performed between low-, medium-, and high-dose SCS groups.

RESULTS:

Twelve trials with 1,375 participates were included. Compared to placebo, the risk of treatment failure was lower in the low-dose SCS groups (risk ratio 0.61 [95% CI 0.43–0.88], P = .007) and high-dose SCS groups (risk ratio 0.64 [95% CI 0.48–0.85], P = .002); the FEV1 was significantly improved in low-dose (mean difference 0.09 [95% CI 0.06–0.12], P < .001), medium-dose (mean difference 0.23 [95% CI 0.02–0.44], P = .036), and high-dose SCS groups (mean difference 0.09, [95% CI 0.03–0.15], P < .001, respectively). Regarding safety, the incidence of hyperglycemia was higher in high-dose SCS groups versus placebo (risk ratio 2.52 [95% CI 1.13–5.62], P = .02). The indirect comparison between low-, medium-, and high-dose SCS found that the risk of treatment failure and changes in FEV1 were similar between these doses of SCS.

CONCLUSIONS:

This meta-analysis indicates that low-dose SCS (initial dose ≤ 40 mg PE/d) was sufficient and safer for treating subjects with COPD exacerbation, and it was noninferior to higher doses of SCS (initial dose > 40 mg PE/d) in improving FEV1 and reducing the risk of treatment failure. However, our findings need to be verified in head-to-head randomized controlled trials.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
冷静如松完成签到 ,获得积分10
7秒前
9秒前
浮云完成签到 ,获得积分10
10秒前
屈岂愈完成签到,获得积分10
11秒前
25秒前
Pupil完成签到,获得积分10
25秒前
偏偏意气用事完成签到,获得积分10
26秒前
安安完成签到,获得积分10
30秒前
cttc完成签到,获得积分10
31秒前
Chnimike完成签到 ,获得积分10
31秒前
35秒前
红茸茸羊完成签到 ,获得积分10
35秒前
年轻千愁完成签到 ,获得积分10
37秒前
liu完成签到,获得积分10
38秒前
量子星尘发布了新的文献求助10
38秒前
Wanyeweiyu完成签到,获得积分10
40秒前
Fury完成签到 ,获得积分10
45秒前
风中幻梦完成签到,获得积分10
47秒前
bigpluto完成签到,获得积分10
48秒前
50秒前
是谁还没睡完成签到 ,获得积分10
51秒前
盘尼西林发布了新的文献求助10
55秒前
zzz完成签到 ,获得积分10
57秒前
dktrrrr完成签到,获得积分10
59秒前
科研通AI2S应助科研通管家采纳,获得10
59秒前
丘比特应助科研通管家采纳,获得20
59秒前
59秒前
ccc完成签到,获得积分10
1分钟前
萧秋灵完成签到,获得积分10
1分钟前
缓慢冥幽完成签到,获得积分10
1分钟前
旺仔同学完成签到,获得积分10
1分钟前
吉以寒完成签到,获得积分10
1分钟前
科研老兵完成签到,获得积分10
1分钟前
量子星尘发布了新的文献求助10
1分钟前
fys131415完成签到 ,获得积分10
1分钟前
执着的忆雪完成签到 ,获得积分10
1分钟前
1分钟前
闵不悔完成签到,获得积分10
1分钟前
阳光火车完成签到 ,获得积分10
1分钟前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038066
求助须知:如何正确求助?哪些是违规求助? 3575779
关于积分的说明 11373801
捐赠科研通 3305584
什么是DOI,文献DOI怎么找? 1819239
邀请新用户注册赠送积分活动 892655
科研通“疑难数据库(出版商)”最低求助积分说明 815022